Mesoblast Limited (MESO) rose 12.40 percent to $12.24 on Tuesday after announcing it reached alignment with the FDA on requirements to file a Biologics License Application for Revascor, aimed at treating ischemic heart failure patients with reduced ejection fraction and inflammation.
Shares opened at $12.00, moved between $11.72 and $12.50 on the Nasdaq, and traded 254,644 shares, above the 206,195 averages, as investors welcomed the FDA progress.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.